PT - JOURNAL ARTICLE AU - Samer Singh AU - Amita Diwaker AU - Rakesh K. Singh TI - ZINC SUFFICIENCY AND COVID-19 MORTALITY IN SOCIALLY SIMILAR EUROPEAN POPULATIONS AID - 10.1101/2020.11.04.20151290 DP - 2021 Jan 01 TA - medRxiv PG - 2020.11.04.20151290 4099 - http://medrxiv.org/content/early/2021/02/03/2020.11.04.20151290.short 4100 - http://medrxiv.org/content/early/2021/02/03/2020.11.04.20151290.full AB - The effect of Zinc (Zn) supplementation or the sufficiency of populations on the occurrence of COVID-19 and associated severe illness/mortality remains unknown. There is a dearth of evidence suggesting any potential protective role for Zn supplementation in COVID-19. However, the general deficiency of Zn in populations, combined with the requirement of optimal Zn levels for immune competence and milder side effects associated with its overdosing in the healthy, have contributed to its widespread inclusion as part of general prescriptions for COVID-19 as well as an immunity booster during the COVID-19 pandemic. Over the counter purchases of Zn supplements have seen an upward trend during the pandemic. Expectedly, multiple trials are underway to ascertain/identify the positive effect of Zn supplementation on COVID-19 infection and mortality when given in combination with standard of care treatments. However, the designs of trials seem to lack the power to identify negative effects especially in the identified vulnerable groups prone to adverse outcomes. When we analyze the COVID-19 data from 23 socially similar European populations/countries with supposedly comparable confounders (population: 522.47 million; experiencing up to >150 fold difference in death rates) and stage of the pandemic from 12 March - 26 June 2020 (1st wave of infections); the populations’ Zn-sufficiency status is found consistently positively correlated with COVID-19 mortality (r(23): 0.7893–0.6849, p-value<0.0003) as well as infections ([r(23):0.8084 to 0.5658; p-value<0.005) for the period. The known existence of a small percentage (2-6%) of adults/elderly with conditions/comorbidities in the populations susceptible to higher Zn intake/supplementation related pathologies could be suspected for the paradoxical observation. Controlled trials or retrospective analysis of the adverse event patients’ data seem warranted for ascertaining the basis of the observation in uncertain terms to allow the harnessing of the full protective potential of the Zn supplementation for populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding has been received for the work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript/references provided.